Crohns disease, Inflammatory bowel disease
SYRESpyre Therapeutics IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for SPY001 (α4β7) in Crohns disease, Inflammatory bowel disease. The expected timing is based on the latest available company guidance and may change.
03/16/26:- SKYLINE UC platform enrolling ahead of schedule; Part A readouts begin Q2 2026. 04/13/26:- Positive 12-week Phase 2 SKYLINE Part A data. Part A recruitment closed; Part B enrolling; induction data 2027. 05/05/26:- SPY001 SKYLINE Part A topline showed strong histologic, remission, endoscopic responses; safety consistent. Part B induction data 2027. 08/04/26:- SKYLINE SPY001 data detailed; Part B induction data expected 2027.
Verification
Confirm timing and program details against the company announcement or filing.